[Preparation and clinical use of a new factor IX concentrate].
Factor IX concentrate was obtained using DEAE-Sephadex A-50 as an adsorbent. The yield of factor IX in vitro averaged 81%. Each bottle of the concentrate contained 288-512 u. of factor II, 96--360 u. of factor VII, 440--660 u. of factor IX and 256--680 u. of factor X. The results of studies showed trace amounts of factor Xa in the final product, in the range of 0.01--0.04 u/ml. The concentrate was found to be free of thrombin. In the years 1976--1977 the new concentrate was administered 48 times to 10 patients with severe haemophilia B. The in vivo recovery of factor IX was 27--65%. Clinical results of treatment were satisfactory in all patients. No significant changes were observed in platelet count, fibrinogen level and the concentration of fibrinogen degradation products after infusion of the concentrate. The ethanol gelation test was negative in all cases.
D000293:Adolescent; D000328:Adult; D005164:Factor IX; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D008722:Methods; D008875:Middle Aged
D005164:Factor IX
Doświadczenia w preparatyce i klinicznym stosowaniu nowego koncentratu czynnika IX.